Brief: Alimera Announces Pricing, Reimbursement Of Uveitis Indication Granted For Iluvien In France
22/07/2022 13:06
July 22 (Reuters) - Alimera Sciences Inc ALIM.O :
* ALIMERA ANNOUNCES PRICING AND REIMBURSEMENT OF UVEITIS
INDICATION GRANTED FOR ILUVIEN® IN FRANCE
Source text for Eikon: ID:nGNX6Gr0mW
Further company coverage: ALIM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger